CME credits: 1.50

Valid until: 30-08-2023

Claim your CME credit at https://reachmd.com/programs/cme/how-does-the-safety-and-tolerability-with-iberdomide-compare-to-current-imid-therapies/14331/

With the introduction of both immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide, and the use of these in combination with drugs from other classes, IMiDs have made a dramatic progress in the treatment of multiple myeloma (MM). However, despite improvement in outcomes, patients with MM ultimately relapse and must undergo further treatment. Early studies show that Cereblon E3 Ligase Modulators (CELMoDs®) iberdomide and CC-92480 show similar trends in activity in patients refractory to IMiDs. This new next generation of IMIDs have shown enhanced tumoricidal and immune-stimulatory effects compared with first-generation IMiDs and have the potential to replace the current standard of care in both frontline and RRMM. This program covers the benefits as well as current challenges with the use of first-generation IMiDs while exploring the MOA, clinical, and safety activity to date of selective CELMoD® therapy in MM.

CME credits: 1.50

Valid until: 30-08-2023

Claim your CME credit at https://reachmd.com/programs/cme/iberdomide-in-combination-with-dexamethasone-in-relapsedrefractory-multiple-myeloma-results-from-the-anti-bcma-exposed-cohort-of-the-cc-220-mm-001-trial/14336/

With the introduction of both immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide, and the use of these in combination with drugs from other classes, IMiDs have made a dramatic progress in the treatment of multiple myeloma (MM). However, despite improvement in outcomes, patients with MM ultimately relapse and must undergo further treatment. Early studies show that Cereblon E3 Ligase Modulators (CELMoDs®) iberdomide and CC-92480 show similar trends in activity in patients refractory to IMiDs. This new next generation of IMIDs have shown enhanced tumoricidal and immune-stimulatory effects compared with first-generation IMiDs and have the potential to replace the current standard of care in both frontline and RRMM. This program covers the benefits as well as current challenges with the use of first-generation IMiDs while exploring the MOA, clinical, and safety activity to date of selective CELMoD® therapy in MM.

CME credits: 1.50

Valid until: 30-08-2023

Claim your CME credit at https://reachmd.com/programs/cme/what-do-the-mechanistic-differences-between-imid-and-celmod-based-therapies-mean-for-clinical-practice/14328/

With the introduction of both immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide, and the use of these in combination with drugs from other classes, IMiDs have made a dramatic progress in the treatment of multiple myeloma (MM). However, despite improvement in outcomes, patients with MM ultimately relapse and must undergo further treatment. Early studies show that Cereblon E3 Ligase Modulators (CELMoDs®) iberdomide and CC-92480 show similar trends in activity in patients refractory to IMiDs. This new next generation of IMIDs have shown enhanced tumoricidal and immune-stimulatory effects compared with first-generation IMiDs and have the potential to replace the current standard of care in both frontline and RRMM. This program covers the benefits as well as current challenges with the use of first-generation IMiDs while exploring the MOA, clinical, and safety activity to date of selective CELMoD® therapy in MM.

CME credits: 1.50

Valid until: 30-08-2023

Claim your CME credit at https://reachmd.com/programs/cme/emerging-iberdomide-based-combinations-in-multiple-myeloma/14333/

With the introduction of both immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide, and the use of these in combination with drugs from other classes, IMiDs have made a dramatic progress in the treatment of multiple myeloma (MM). However, despite improvement in outcomes, patients with MM ultimately relapse and must undergo further treatment. Early studies show that Cereblon E3 Ligase Modulators (CELMoDs®) iberdomide and CC-92480 show similar trends in activity in patients refractory to IMiDs. This new next generation of IMIDs have shown enhanced tumoricidal and immune-stimulatory effects compared with first-generation IMiDs and have the potential to replace the current standard of care in both frontline and RRMM. This program covers the benefits as well as current challenges with the use of first-generation IMiDs while exploring the MOA, clinical, and safety activity to date of selective CELMoD® therapy in MM.

CME credits: 1.50

Valid until: 30-08-2023

Claim your CME credit at https://reachmd.com/programs/cme/how-does-the-safety-and-tolerability-with-iberdomide-compare-to-current-imid-therapies/14332/

With the introduction of both immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide, and the use of these in combination with drugs from other classes, IMiDs have made a dramatic progress in the treatment of multiple myeloma (MM). However, despite improvement in outcomes, patients with MM ultimately relapse and must undergo further treatment. Early studies show that Cereblon E3 Ligase Modulators (CELMoDs®) iberdomide and CC-92480 show similar trends in activity in patients refractory to IMiDs. This new next generation of IMIDs have shown enhanced tumoricidal and immune-stimulatory effects compared with first-generation IMiDs and have the potential to replace the current standard of care in both frontline and RRMM. This program covers the benefits as well as current challenges with the use of first-generation IMiDs while exploring the MOA, clinical, and safety activity to date of selective CELMoD® therapy in MM.

CME credits: 1.50

Valid until: 30-08-2023

Claim your CME credit at https://reachmd.com/programs/cme/will-i-be-able-to-use-celmods-in-imid-refractory-patients/14329/

With the introduction of both immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide, and the use of these in combination with drugs from other classes, IMiDs have made a dramatic progress in the treatment of multiple myeloma (MM). However, despite improvement in outcomes, patients with MM ultimately relapse and must undergo further treatment. Early studies show that Cereblon E3 Ligase Modulators (CELMoDs®) iberdomide and CC-92480 show similar trends in activity in patients refractory to IMiDs. This new next generation of IMIDs have shown enhanced tumoricidal and immune-stimulatory effects compared with first-generation IMiDs and have the potential to replace the current standard of care in both frontline and RRMM. This program covers the benefits as well as current challenges with the use of first-generation IMiDs while exploring the MOA, clinical, and safety activity to date of selective CELMoD® therapy in MM.

CME credits: 1.50

Valid until: 30-08-2023

Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-response-and-safety-profile-with-iberdomide-based-therapies-in-multiple-myeloma/14330/

With the introduction of both immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide, and the use of these in combination with drugs from other classes, IMiDs have made a dramatic progress in the treatment of multiple myeloma (MM). However, despite improvement in outcomes, patients with MM ultimately relapse and must undergo further treatment. Early studies show that Cereblon E3 Ligase Modulators (CELMoDs®) iberdomide and CC-92480 show similar trends in activity in patients refractory to IMiDs. This new next generation of IMIDs have shown enhanced tumoricidal and immune-stimulatory effects compared with first-generation IMiDs and have the potential to replace the current standard of care in both frontline and RRMM. This program covers the benefits as well as current challenges with the use of first-generation IMiDs while exploring the MOA, clinical, and safety activity to date of selective CELMoD® therapy in MM.

CME credits: 1.50

Valid until: 30-08-2023

Claim your CME credit at https://reachmd.com/programs/cme/panel-celmods-a-novel-advance-or-another-imid/14334/

With the introduction of both immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide, and the use of these in combination with drugs from other classes, IMiDs have made a dramatic progress in the treatment of multiple myeloma (MM). However, despite improvement in outcomes, patients with MM ultimately relapse and must undergo further treatment. Early studies show that Cereblon E3 Ligase Modulators (CELMoDs®) iberdomide and CC-92480 show similar trends in activity in patients refractory to IMiDs. This new next generation of IMIDs have shown enhanced tumoricidal and immune-stimulatory effects compared with first-generation IMiDs and have the potential to replace the current standard of care in both frontline and RRMM. This program covers the benefits as well as current challenges with the use of first-generation IMiDs while exploring the MOA, clinical, and safety activity to date of selective CELMoD® therapy in MM.

CME credits: 0.50

Valid until: 25-08-2023

Claim your CME credit at https://reachmd.com/programs/cme/evolving-perspectives-in-pik3ca-related-overgrowth-spectrum-diagnosis-treatment/13790/

PIK3CA-related overgrowth spectrum (PROS) refers to various clinical entities that share the same pathogenetic mechanism. These disorders are caused by somatic gain-of-function PIK3CA mutations. Diagnosis of PROS is often challenging and requires DNA sequencing of the affected tissue. PIK3CA genetic mutations vary greatly depending on the tissue being tested. PROS is not considered an inherited disease.

The road to a diagnosis of a rare disease can be a long, winding process. Because of its rarity, a wide spectrum of symptoms, and disease heterogeneity, patients may feel alone and as though they are the only ones with the disease. Management of PROS currently involves symptomatic treatment of its manifestations; an unmet need exists for targeted, systemic therapies.

Currently, there is no cure for PROS. This educational activity will assist the interprofessional care team to better understand, apply, and interpret advances in current and emerging evidence that will help bridge the gap toward faster adoption into patient care.

=

CME credits: 0.25

Valid until: 26-08-2023

Claim your CME credit at https://reachmd.com/programs/cme/looking-beyond-diabetes-the-role-of-sglt2i-and-mras-in-cardiorenal-disease/13259/

Optimizing GDMT for patients with heart failure and concomitant kidney dysfunction and/or diabetes continues to be a challenge despite the overwhelming clinical evidence and recent updates to the guidelines for heart failure management. Recent evidence from clinical trials with SGLT2 inhibitors and mineralocorticoid receptor antagonists and the use of novel potassium binders provide new therapeutic opportunities for these patients. This activity will review the current challenges in initiating and maintaining patients on optimal RAASi therapy and approaches to improve cardiorenal outcomes.

=